The glucagon‐like peptide‐1 and other endocrine responses to alcohol ingestion in women with versus without metabolic surgery

Documenti analoghi

• Re: The association between glucose‐dependent insulinotropic polypeptide and/or glucagon‐like peptide‐1 receptor agonist prescriptions and substance‐related outcomes in patients with opioid and alcohol use disorders: A real‐world data analysis
  di: Yanning Wang, et al.
  Pubblicazione: (2025)
• Glucagon‐like peptide‐1 receptor agonists in alcohol use disorder: Multi‐system effects, early clinical promise and uncertain long‐term use
  di: Carolina L. Haass‐Koffler
  Pubblicazione: (2026)
• Circulating Immune and Endocrine Markers in Currently Drinking and Abstinent Individuals With Alcohol Use Disorder and Controls
  di: Ryan E. Tyler, et al.
  Pubblicazione: (2025)
• Impact of bariatric surgery on alcohol‐use disorder and alcohol‐related liver disease: A retrospective study
  di: Thomas J. Williams, et al.
  Pubblicazione: (2026)
• Reduced drug use as an alternative valid outcome in individuals with stimulant use disorders: Findings from 13 multisite randomized clinical trials
  di: Masoumeh Amin‐Esmaeili, et al.
  Pubblicazione: (2024)